Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details)

v3.20.2
Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares
shares in Thousands
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Antidilutive securities excluded from computation of diluted weighted shares outstanding 26,448 24,220
PAVmed Inc. 2014 Equity Plan Stock Options and Restricted Awards [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 7,965 5,804
Unit Purchase Options as to Shares of common stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53 53
Unit Purchase Options as to Shares Underlying Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 53 53
Series Z Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 16,815 16,815
Series W Warrants [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 382 382
Series B Convertible Preferred Stock [Member]    
Antidilutive securities excluded from computation of diluted weighted shares outstanding 1,180 1,113